AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31171878 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet therapy (dabrafenib, trametinib, pembrolizumab)
Number of subjects: 120
Study 31171878 — intervention group
Group type: COMPARATOR
Intervention: Doublet therapy (dabrafenib, trametinib, placebo)
Number of subjects: 120
Study 29162875 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AEx)
Number of subjects: 115
Study 29162875 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (Diet)
Number of subjects: 115
Study 29162875 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus diet (AED)
Number of subjects: 115
Study 29162875 — intervention group
Group type: COMPARATOR
Intervention: No-intervention (NI)
Number of subjects: 115
Study 25716883 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Kirschner-wire fixation
Number of subjects: 461
Study 25716883 — intervention group
Group type: COMPARATOR
Intervention: Volar locking-plate fixation
Number of subjects: 461
Study 25716883 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirschner-wire fixation
Number of subjects: 461
Study 25716883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 461
Study 24628035 — intervention group
Group type: COMPARATOR
Intervention: TA-8995 (5, 10, 25, 50, 100, 150 mg single doses; 1, 2.5, 10, 25 mg once daily for 21-28 days)
Number of subjects: 0
Study 24628035 — intervention group
Group type: COMPARATOR
Intervention: TA-8995 (2.5 to 25 mg once daily)
Number of subjects: 0
Study 24628035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21887500 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD + rhGDF‐5/β‐TCP
Number of subjects: 20
Study 21887500 — intervention group
Group type: COMPARATOR
Intervention: OFD alone (control)
Number of subjects: 20
Study 19200119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% conjugated linoleic acid (CLA)
Number of subjects: 24
Study 19200119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% sodium tripolyphosphate (PHO)
Number of subjects: 24
Study 19200119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% salt (SAL)
Number of subjects: 24
Study 19200119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% sodium tripolyphosphate, 0.5% salt (SPH)
Number of subjects: 24
Study 19200119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% sodium tripolyphosphate, 1.5% CLA (PCL)
Number of subjects: 24
Study 19200119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% salt, 1.5% CLA (SCL)
Number of subjects: 24
Study 19200119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% sodium tripolyphosphate, 0.5% salt, 1.5% CLA (SPC)
Number of subjects: 24
Study 19200119 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA (inclusion in fresh steaks)
Number of subjects: 24
Study 19200119 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA (inclusion in cooked steaks)
Number of subjects: 24
Study 19200119 — intervention group
Group type: EXPERIMENTAL
Intervention: Day
Number of subjects: 24
Study 19200119 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment x day interactions
Number of subjects: 24
Study 17539715 — intervention group
Group type: EXPERIMENTAL
Intervention: Crown-lengthening surgery (CLS)
Number of subjects: 19
Study 15242422 — intervention group
Group type: EXPERIMENTAL
Intervention: [(18)F]fluoro‐2‐deoxy‐d‐glucose (FDG) positron emission tomography
Number of subjects: 31
Study 15242422 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 31
Study 11098982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciaglia PDT kit
Number of subjects: 100
Study 11098982 — intervention group
Group type: COMPARATOR
Intervention: Griggs PDT kit
Number of subjects: 100
Study 9298173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 15
Study 9298173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8145485 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOLs
Number of subjects: 125
Study 8145485 — intervention group
Group type: COMPARATOR
Intervention: PMMA IOLs
Number of subjects: 125
Study 3533567 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg capsules of nifedipine
Number of subjects: 12
Study 3533567 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg capsules of nifedipine
Number of subjects: 12
Study 3533567 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg capsules of nifedipine
Number of subjects: 12
Study 3533567 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tablets of nifedipine
Number of subjects: 12
Study 3533567 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of nifedipine
Number of subjects: 12
Study 3533567 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg and 20 mg capsules and 20 mg tablets
Number of subjects: 12
Study 3533567 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine tablets
Number of subjects: 12
Study 31778632 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg IV)
Number of subjects: 26
Study 31778632 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide (500 mg IV)
Number of subjects: 26
Study 28420629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg intravenous at induction of anaesthesia)
Number of subjects: 1350
Study 28420629 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1350
Study 25606834 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment (5 mV, 650 nm, 20 minutes a day, 5 days a week for 4 weeks)
Number of subjects: 66
Study 25606834 — intervention group
Group type: COMPARATOR
Intervention: Inactive dummy treatment (placebo)
Number of subjects: 66
Study 24307207 — intervention group
Group type: EXPERIMENTAL
Intervention: zuclopenthixol at a dose of 2-20 mg/d
Number of subjects: 49
Study 24307207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 20884014 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor clinical impairment RRMS patients (n=33)
Number of subjects: 98
Study 20884014 — intervention group
Group type: EXPERIMENTAL
Intervention: Major clinical impairment RRMS patients (n=25)
Number of subjects: 98
Study 20884014 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=40)
Number of subjects: 98
Study 20884014 — intervention group
Group type: EXPERIMENTAL
Intervention: RRMS patients (minor and major)
Number of subjects: 98
Study 19405040 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucaffect
Number of subjects: 50
Study 19405040 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 17317388 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Eye Syndrome (DES)
Number of subjects: 690
Study 15220318 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia (inspired O(2) fraction = 0.21)
Number of subjects: 10
Study 15220318 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia (inspired O(2) fraction = 0.14)
Number of subjects: 10
Study 11598604 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH treatment (28 IU/m2/wk)
Number of subjects: 481
Study 10401821 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupet fundoplication (TF)
Number of subjects: 256
Study 10401821 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication (NF)
Number of subjects: 256
Study 7575274 — intervention group
Group type: EXPERIMENTAL
Intervention: Decapinol mouthwash 2 mg/mL
Number of subjects: 47
Study 7575274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 2105988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) administration
Number of subjects: 270
Study 2105988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 6157203 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole nitrate 150 mg per day for 3 days
Number of subjects: 0
Study 6157203 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole nitrate 50 mg per day for 14 days
Number of subjects: 0
Study 6157203 — intervention group
Group type: COMPARATOR
Intervention: Econazole nitrate (both regimens)
Number of subjects: 0
Study 30152573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal OXT (24 IU)
Number of subjects: 194
Study 30152573 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner support (handholding)
Number of subjects: 194
Study 30152573 — intervention group
Group type: COMPARATOR
Intervention: Control (unfamiliar person support)
Number of subjects: 194
Study 30152573 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural response to shocks
Number of subjects: 194
Study 30152573 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional coupling between AI and MFG
Number of subjects: 194
Study 27791246 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 mm with biaxial microincision phacoemulsification (25 eyes)
Number of subjects: 90
Study 27791246 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 mm with coaxial phacoemulsification (62 eyes)
Number of subjects: 90
Study 27791246 — intervention group
Group type: COMPARATOR
Intervention: 1.8 mm with coaxial phacoemulsification (27 eyes)
Number of subjects: 90
Study 25547068 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (n = 10)
Number of subjects: 21
Study 25547068 — intervention group
Group type: COMPARATOR
Intervention: Non-Trained group (n = 11)
Number of subjects: 21
Study 23955709 — intervention group
Group type: EXPERIMENTAL
Intervention: 25,000 IU retinyl palmitate capsule daily for 6 months
Number of subjects: 0
Study 23955709 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule daily for 6 months
Number of subjects: 0
Study 21828156 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (Mozart's Sonata for Two Pianos in D Major)
Number of subjects: 160
Study 21828156 — intervention group
Group type: EXPERIMENTAL
Intervention: Headphones (noise-cancellation headphones, no music)
Number of subjects: 160
Study 21828156 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 19216763 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT) consisting of mobilisations, exercise therapy for the cervical and thoracic spine, and postural correction.
Number of subjects: 0
Study 19216763 — intervention group
Group type: COMPARATOR
Intervention: Usual care by the general practitioner (GP) according to national Dutch general practice guidelines for headache.
Number of subjects: 0
Study 19216763 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Number of subjects: 0
Study 19216763 — intervention group
Group type: COMPARATOR
Intervention: Usual care by the general practitioner (GP)
Number of subjects: 0
Study 17646620 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patches
Number of subjects: 1059
Study 12927313 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day)
Number of subjects: 64
Study 12927313 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (1 tab/day, placebo)
Number of subjects: 64
Study 11004055 — intervention group
Group type: EXPERIMENTAL
Intervention: Local dermatomal stimulation
Number of subjects: 68
Study 11004055 — intervention group
Group type: COMPARATOR
Intervention: Needles only
Number of subjects: 68
Study 11004055 — intervention group
Group type: COMPARATOR
Intervention: Remote dermatomal stimulation
Number of subjects: 68
Study 9000318 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment (traditional antipsychotic drugs)
Number of subjects: 44
Study 1361435 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (alpha 1-receptor-blocking compound)
Number of subjects: 20
Study 1361435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6437263 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg D2343
Number of subjects: 8
Study 6437263 — intervention group
Group type: COMPARATOR
Intervention: 5 mg terbutaline
Number of subjects: 8
Study 3723158 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol
Number of subjects: 0
Study 3723158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol
Number of subjects: 0
Study 29493361 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Support System (DSS) for glucose prediction during hypoglycemia or hyperglycemia events
Number of subjects: 12
Study 29493361 — intervention group
Group type: COMPARATOR
Intervention: Control phase (CP) where patients followed decisions without knowing the glucose prediction
Number of subjects: 12
Study 29493361 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability of the DSS
Number of subjects: 12
Study 27291982 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based training program for caregivers of AD patients
Number of subjects: 114
Study 27291982 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based training program for caregivers of VaD patients
Number of subjects: 114
Study 27291982 — intervention group
Group type: COMPARATOR
Intervention: Control group for caregivers of AD patients
Number of subjects: 114
Study 27291982 — intervention group
Group type: COMPARATOR
Intervention: Control group for caregivers of VaD patients
Number of subjects: 114
Study 24560278 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg/day for 4 months
Number of subjects: 54
Study 24560278 — intervention group
Group type: COMPARATOR
Intervention: Zinc supplementation 30mg/day
Number of subjects: 54
Study 22527372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 56
Study 22527372 — intervention group
Group type: COMPARATOR
Intervention: Conventional Coronary Angiography (CCA)
Number of subjects: 56
Study 20237029 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (100 mg every 4 h for 6 days)
Number of subjects: 72
Study 19000845 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized educational session and provision of 200 folate tablets
Number of subjects: 446
Study 19000845 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 446
Study 15992223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 90
Study 15992223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg)
Number of subjects: 90
Study 15992223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 14634409 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg, adjustable to 100 or 25 mg)
Number of subjects: 202
Study 14634409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 10995004 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-cis retinoic acid (9CRA) at 60 mg/m2 daily for 1 week, then escalating to 100 mg/m2 during the second week, up to a maximum of 140 mg/m2 for a planned duration of 48 weeks.
Number of subjects: 30
Study 10995004 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-cis retinoic acid (9CRA)
Number of subjects: 30
Study 8626872 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 11
Study 8626872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1469177 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Decontamination of the Digestive Tract (SDD) with Cefotaxime i.v. (6 g/day) for the first four days and Polymyxin E, Tobramycin and Amphotericin B at the oropharyngeal and gastrointestinal level throughout the whole stay
Number of subjects: 101
Study 1469177 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Decontamination of the Digestive Tract (SDD)
Number of subjects: 101
Study 6378145 — intervention group
Group type: EXPERIMENTAL
Intervention: One knife
Number of subjects: 586
Study 6378145 — intervention group
Group type: COMPARATOR
Intervention: Two knives
Number of subjects: 586
Study 30101278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 0
Study 30101278 — intervention group
Group type: COMPARATOR
Intervention: Morphine (Control)
Number of subjects: 0
Study 29540661 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 900 mg/day for 7 days before surgery
Number of subjects: 70
Study 29540661 — intervention group
Group type: COMPARATOR
Intervention: Control (no N-acetylcysteine)
Number of subjects: 70
Study 26963952 — intervention group
Group type: EXPERIMENTAL
Intervention: Older men with age-related low T levels (4% positive for antipituitary antibodies)
Number of subjects: 182
Study 26963952 — intervention group
Group type: COMPARATOR
Intervention: Healthy young and older eugonadal men (0% positive for antipituitary antibodies)
Number of subjects: 182
Study 24687829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing therapy (BEV-CT)
Number of subjects: 361
Study 24687829 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (CT)
Number of subjects: 361
Study 22574084 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized iron supplementation program (B group)
Number of subjects: 360
Study 22574084 — intervention group
Group type: COMPARATOR
Intervention: Control group with free iron tablets (A group)
Number of subjects: 360
Study 20565514 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg daily) plus counselling
Number of subjects: 82
Study 20565514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 17553747 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information delivery
Number of subjects: 99
Study 17553747 — intervention group
Group type: COMPARATOR
Intervention: Written information delivery
Number of subjects: 99
Study 17553747 — intervention group
Group type: COMPARATOR
Intervention: Audiovisual information delivery
Number of subjects: 99
Study 16200253 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (5 g/day for 28 days)
Number of subjects: 46
Study 16200253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 12857697 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one interviews with faculty
Number of subjects: 68
Study 12857697 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical incident report (CIR) followed by one-on-one interview
Number of subjects: 68
Study 12857697 — intervention group
Group type: COMPARATOR
Intervention: One-on-one interviews with no CIR
Number of subjects: 68
Study 12857697 — intervention group
Group type: COMPARATOR
Intervention: Critical incident report (CIR)
Number of subjects: 68
Study 10758459 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 8987965 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-day walking group (n = 17)
Number of subjects: 56
Study 8987965 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day walking group (n = 19)
Number of subjects: 56
Study 8987965 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (n = 20)
Number of subjects: 56
Study 1290634 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium pamidronate (APD) administered as a single i.v. infusion of 30, 60 or 90 mg depending on serum calcium.
Number of subjects: 25
Study 1290634 — intervention group
Group type: COMPARATOR
Intervention: Mithramycin given in doses of 1.25 mg, repeated if necessary within the first three days.
Number of subjects: 25
Study 3937509 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg tablets, 1 tablet twice daily)
Number of subjects: 59
Study 3937509 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg tablets, 1 tablet every morning)
Number of subjects: 59
Study 30785667 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin (GG)
Number of subjects: 120
Study 30785667 — intervention group
Group type: COMPARATOR
Intervention: Laxative bowel preparation (LBP)
Number of subjects: 120
Study 30045006 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg in the morning and 5 mg at bedtime for 12 months)
Number of subjects: 60
Study 30045006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 x 1 tablet for 12 months)
Number of subjects: 60
Study 26223511 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Emotional Disclosure (WED)
Number of subjects: 24
Study 26223511 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing task (Control)
Number of subjects: 24
Study 26223511 — intervention group
Group type: COMPARATOR
Intervention: Comparison of emotional content
Number of subjects: 24
Study 24675168 — intervention group
Group type: EXPERIMENTAL
Intervention: L6 diet (average n‐3, low n‐6)
Number of subjects: 0
Study 24675168 — intervention group
Group type: EXPERIMENTAL
Intervention: H3-L6 diet (high n‐3, low n‐6 LA)
Number of subjects: 0
Study 22585767 — intervention group
Group type: EXPERIMENTAL
Intervention: suma/nap 10/60 mg
Number of subjects: 490
Study 22585767 — intervention group
Group type: EXPERIMENTAL
Intervention: suma/nap 30/180 mg
Number of subjects: 490
Study 22585767 — intervention group
Group type: EXPERIMENTAL
Intervention: suma/nap 85/500 mg
Number of subjects: 490
Study 22585767 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 490
Study 19892351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet plus 40 mg/day of pravastatin
Number of subjects: 180
Study 19892351 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 180
Study 18697875 — intervention group
Group type: COMPARATOR
Intervention: GH replacement
Number of subjects: 268
Study 16038474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 1077
Study 16038474 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 1077
Study 12208704 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary phacoemulsification and intraocular lens implantation (PPI)
Number of subjects: 43
Study 12208704 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical iridectomy (CSI)
Number of subjects: 43
Study 10512282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (286 mg, 66 mL)
Number of subjects: 58
Study 10512282 — intervention group
Group type: COMPARATOR
Intervention: Saline (66 mL)
Number of subjects: 58
Study 7593149 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxerutin
Number of subjects: 85
Study 7593149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 2177648 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 20 mg/day for 12 days each calendar month for 3 months, then 10 mg/day for a further 3 months
Number of subjects: 16